Previous 10 | Next 10 |
2023-05-09 04:02:31 ET Summary Despite the recent rebound, US-listed biotech stocks valuations are still "down to earth" compared to the strong recovery from the Covid-19 crisis. Relatively low market valuations offer an opportunity to add to positions in biotechnology stocks with...
2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
2023-04-06 10:11:48 ET Shares of clinical-stage biotech Janux Therapeutics ( NASDAQ: JANX ) inched higher Thursday after Wedbush launched its coverage with an Outperform recommendation, citing the potential of its platform technology. Janux ( JANX ) develops immunotherapies ...
2023-03-15 11:44:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stoc...
2023-03-10 16:37:09 ET Janux Therapeutics press release ( NASDAQ: JANX ): Q4 GAAP EPS of -$0.39 beats by $0.10 . Revenue of $2.85M (+75.9% Y/Y) beats by $2.04M . For further details see: Janux Therapeutics GAAP EPS of -$0.39 beats by $0.10, revenue of $2....
-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008)- -$327.0 million in year-end cash and cash equivalents and short-term investments- Janux Therapeutics...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans. The company added that JANX008 is in development to treat EGFR-e...
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
Janux Therapeutics Inc. Website:
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board me...
2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...